| ESTA |
Establishment Labs Holdings Inc. |
72%
|
Reciprocal relationship from ESTA graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from ESTA graph: Reciprocal relationship from CLGN graph: an cadavers. The main competitors t… |
| ESTA |
Establishment Labs Holdings Inc. |
72%
|
an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
| IMCC |
IM Cannabis Corp. |
72%
|
es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evol… |
| IMCC |
IM Cannabis Corp. |
72%
|
Reciprocal relationship from IMCC graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from IMCC graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from IMCC g… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from CLGN graph: funds are secured for its execution. While our upstream and downstream processes are quite robust and efficient, we co… |
| JNJ |
Johnson & Johnson |
72%
|
funds are secured for its execution. While our upstream and downstream processes are quite robust and efficient, we continuously invest in further yield improvement and scalability, in order to reduc… |
| KLIC |
Kulicke and Soffa Industries, Inc. |
72%
|
es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evol… |
| KLIC |
Kulicke and Soffa Industries, Inc. |
72%
|
Reciprocal relationship from KLIC graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from KLIC graph: Reciprocal relationship from CLGN graph: es and marketing organization, for … |
| RGNT |
Regentis Biomaterials Ltd. |
72%
|
es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evol… |
| RGNT |
Regentis Biomaterials Ltd. |
72%
|
Reciprocal relationship from RGNT graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from RGNT graph: Reciprocal relationship from CLGN graph: Reciprocal relationship from RGNT g… |
| ARTERIOCYTE-MEDICAL-SYSTEMS-INC |
ARTERIOCYTE-MEDICAL-SYSTEMS-INC |
62%
|
an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
| CELLINK-ALLEVI-INC |
CELLINK-ALLEVI-INC |
62%
|
an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
| COLLPLANT-INC-COLLPLANT-INC |
COLLPLANT-INC-COLLPLANT-INC |
62%
|
gardless of our actual operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted … |
| COLLPLANT-LTD |
COLLPLANT-LTD |
62%
|
d revenues of approximately $2.4 million, mainly attributable to a development milestone achievement relating to the dermal filler product candidate, which triggered a $2 million payment from AbbVie … |
| COLLPLANT-LTD-COLLPLANT-LTD |
COLLPLANT-LTD-COLLPLANT-LTD |
62%
|
gardless of our actual operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted … |
| GRAND-VIEW-RESEARCH-INC |
GRAND-VIEW-RESEARCH-INC |
62%
|
ength due to alignment of the collagen fibers, and higher levels of transparency. In addition, rhCollagen can be used to produce high concentration solutions of collagen at lower viscosities at room … |
| MENTOR-WORLDWIDE-LLC |
MENTOR-WORLDWIDE-LLC |
62%
|
an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
gardless of our actual operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted … |
| ORTHOSCAN-TECHNOLOGIES-LTD |
ORTHOSCAN-TECHNOLOGIES-LTD |
62%
|
es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evol… |
| PROCHON-BIOTECH-LTD |
PROCHON-BIOTECH-LTD |
62%
|
es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evol… |
| SOFFA-INDUSTRIES-INC |
SOFFA-INDUSTRIES-INC |
62%
|
es and marketing organization, for the commercialization of our products in Europe; ● the time and costs involved in obtaining regulatory approvals and any delays we may encounter as a result of evol… |
| TASE-COLLPLANT-LTD |
TASE-COLLPLANT-LTD |
62%
|
gardless of our actual operating performance. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted … |
| ZIMMER-BIOMET-HARVEST-TECHNOLOGIES-CORPORATION |
ZIMMER-BIOMET-HARVEST-TECHNOLOGIES-CORPORATION |
62%
|
an cadavers. The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and AbbVie. The main competitors to our 3D bioprint… |
